Dendritic cells and T cells in immunotherapy.
Autologous cellular immunotherapies have been used experimentally in humans to treat many types of cancer. These therapies are divided into two principal types: active cellular immunotherapies that rely on autologous dendritic cells or other antigen presenting cells; and adoptive T-cell therapies, in which large numbers of antigen-specific T lymphocytes are propagated ex vivo and then infused back into the patient. With the FDA approval of the antigen presenting cell vaccine sipuleucel-T for prostate cancer, active immunization has become an accepted approach for the treatment of established cancer.
NYU School of Medicine, NYU Cancer Institute, Vaccine and Cell Therapy Core Laboratory, New York, NY 10011, USA. oneilld8@gmail.com
David W
DW
O'Neill
D019264:Adoptive Transfer; D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D008297:Male; D011471:Prostatic Neoplasms / Q000628:therapy; D013601:T-Lymphocytes / Q000276:immunology*; D014020:Tissue Extracts / Q000276:immunology / Q000627:therapeutic use*
D019496:Cancer Vaccines; D014020:Tissue Extracts; C511774:sipuleucel-T